165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial

Rupert Bartsch, Anna S. Berghoff, Julia Furtner, Maximilian Marhold, Elisabeth Bergen, S. Roider-Schur, Angelika M. Starzer, Heidrun Forstner, Beate Rottenmanner, Karin Dieckmann, Zsuzsanna Bagó-Horváth, Georg Widhalm, Aysegül Ilhan‐Mutlu, Christoph Minichsdorfer, Thorsten Fuereder, C Singer, A. Weltermann, Rainer Puhr, Matthias Preusser